GlassScriptPhysician profile
John A Ricci
NPI 1043383987
$7,379.48
in general payments reported to CMS, 2019-2025
35 companies · $269 in 2025
The $269 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,704 · 2020: $796 · 2021: $1,655 · 2022: $1,011 · 2023: $846 · 2024: $98.50 · 2025: $269.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,213.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,212.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,027.54 | 2019-2024 | |
| Novo Nordisk INC | $1,100.27 | 2019-2022 | |
| Pfizer INC. | $484.08 | 2019-2024 | |
| Biohaven Pharmaceutical Holding Company LTD. | $441.73 | 2022 | |
| Glaxosmithkline, LLC. | $424.54 | 2019-2023 | Arexvy, Shingrix, Trelegy Ellipta |
| Amarin Pharma, INC. | $357.22 | 2019 | |
| Lundbeck LLC | $340.05 | 2019-2025 | Vyepti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $332.13 | 2019-2024 | Relistor |
| Eisai INC. | $204.40 | 2020-2022 | |
| Allergan, INC. | $190.12 | 2019-2020 | |
| Alexion Pharmaceuticals, INC. | $152.96 | 2020-2021 | |
| Galderma Laboratories, L.P. | $150.00 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $141.15 | 2019-2023 | Gammagard |
| Amgen INC. | $124.99 | 2020 | |
| Ars Pharmaceuticals Operations, INC. | $124.97 | 2025 | Neffy |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Optinose US, INC. | $108.90 | 2021 | |
| Genentech USA, INC. | $95.80 | 2019 | |
| Tolmar, INC. | $95.24 | 2023 | |
| Lilly USA, LLC | $80.41 | 2019-2024 | Mounjaro, Zepbound |
| Teva Pharmaceuticals USA, INC. | $56.80 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $50.53 | 2019 | |
| Merck Sharp & Dohme LLC | $44.00 | 2019 | |
| Daiichi Sankyo INC. | $31.63 | 2021-2022 | |
| Nalpropion Pharmaceuticals LLC | $29.23 | 2019 | |
| Sanofi-Aventis U.S. LLC | $26.32 | 2019-2020 | |
| Boston Scientific Corporation | $23.31 | 2025 | General - Pain Management |
| Exact Sciences Corporation | $22.42 | 2023 | Cologuard Collection Kit |
| Clarus Therapeutics INC. | $20.74 | 2021 | |
| Antares Pharma, INC. | $14.70 | 2020 | |
| Endo Pharmaceuticals INC. | $14.63 | 2019 | |
| Orthogenrx INC. | $14.39 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.31 | 2019 | |
| Aytu Biopharma, INC. | $14.29 | 2019 | |
| Halozyme INC | $13.60 | 2023 | |
| Sanofi Pasteur INC. | $12.08 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Ricci listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.